Differential Response to Local Stimulator of Interferon Genes Agonist Administration in Tumors with Various Stimulator of Interferon Genes Statuses
Alina Drzyzga(The Maria Sklodowska-Curie National Research Institute of Oncology), Ryszard Smolarczyk(National Institute of Oncology)
Cited by 2
Related Papers
Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapy
|Cancer Immunology Immunotherapy|2024|14